147 related articles for article (PubMed ID: 31801617)
1. Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer.
Cooper WN; Dickinson RE; Dallol A; Grigorieva EV; Pavlova TV; Hesson LB; Bieche I; Broggini M; Maher ER; Zabarovsky ER; Clark GJ; Latif F
Oncogene; 2008 Mar; 27(12):1805-11. PubMed ID: 17891178
[TBL] [Abstract][Full Text] [Related]
2. Revisiting ZAR proteins: the understudied regulator of female fertility and beyond.
Wu YK; Fan HY
Cell Mol Life Sci; 2022 Jan; 79(2):92. PubMed ID: 35072788
[TBL] [Abstract][Full Text] [Related]
3. Cellular and clinical impact of protein phosphatase enzyme epigenetic silencing in multiple cancer tissues.
Wiltshire E; de Moura MC; Piñeyro D; Joshi RS
Hum Genomics; 2024 Mar; 18(1):24. PubMed ID: 38475971
[TBL] [Abstract][Full Text] [Related]
4. Disruption of Zar1 leads to arrested oogenesis by regulating polyadenylation via Cpeb1 in tilapia (Oreochromis niloticus).
Yu M; Zhang S; Ma Z; Qiang J; Wei J; Sun L; Kocher TD; Wang D; Tao W
Int J Biol Macromol; 2024 Mar; 260(Pt 2):129632. PubMed ID: 38253139
[TBL] [Abstract][Full Text] [Related]
5. Biomarker RIPK3 Is Silenced by Hypermethylation in Melanoma and Epigenetic Editing Reestablishes Its Tumor Suppressor Function.
Arroyo Villora S; Castellanos Silva P; Zenz T; Kwon JS; Schlaudraff N; Nitaj D; Meckbach C; Dammann R; Richter AM
Genes (Basel); 2024 Jan; 15(2):. PubMed ID: 38397165
[TBL] [Abstract][Full Text] [Related]
6. BRCA1 Promoter Hypermethylation in Malignant Breast Tumors and in the Histologically Normal Adjacent Tissues to the Tumors: Exploring Its Potential as a Biomarker and Its Clinical Significance in a Translational Approach.
Oubaddou Y; Oukabli M; Fenniche S; Elktaibi A; Elochi MR; Al Bouzidi A; Qmichou Z; Dakka N; Diorio C; Richter A; Bakri Y; Ameziane El Hassani R
Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761820
[TBL] [Abstract][Full Text] [Related]
7. Assay for Transposase-Accessible Chromatin Using Sequencing of Freshly Isolated Muscle Stem Cells.
Yekelchyk M; Guenther S; Braun T
Methods Mol Biol; 2023; 2640():397-412. PubMed ID: 36995609
[TBL] [Abstract][Full Text] [Related]
8. Low expression of PRDM5 predicts poor prognosis of esophageal squamous cell carcinoma.
Guo J; Yang Q; Wei S; Shao J; Zhao T; Guo L; Liu J; Chen J; Wang G
BMC Cancer; 2022 Jul; 22(1):745. PubMed ID: 35799142
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic Editing in Prostate Cancer: Challenges and Opportunities.
Pacheco MB; Camilo V; Henrique R; Jerónimo C
Epigenetics; 2022 May; 17(5):564-588. PubMed ID: 34130596
[TBL] [Abstract][Full Text] [Related]
10. First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancer.
Cheng H; Zou Y; Shah CD; Fan N; Bhagat TD; Gucalp R; Kim M; Verma A; Piperdi B; Spivack SD; Halmos B; Perez-Soler R
Lung Cancer; 2021 Apr; 154():99-104. PubMed ID: 33636454
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic Inactivation of the Tumor Suppressor
Küster MM; Schneider MA; Richter AM; Richtmann S; Winter H; Kriegsmann M; Pullamsetti SS; Stiewe T; Savai R; Muley T; Dammann RH
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33256112
[No Abstract] [Full Text] [Related]
12. Epigenetic therapy of novel tumour suppressor ZAR1 and its cancer biomarker function.
Deutschmeyer V; Breuer J; Walesch SK; Sokol AM; Graumann J; Bartkuhn M; Boettger T; Rossbach O; Richter AM
Clin Epigenetics; 2019 Dec; 11(1):182. PubMed ID: 31801617
[TBL] [Abstract][Full Text] [Related]
13. The ZAR1 protein in cancer; from epigenetic silencing to functional characterisation and epigenetic therapy of tumour suppressors.
Deutschmeyer VE; Richter AM
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188417. PubMed ID: 32828887
[TBL] [Abstract][Full Text] [Related]
14. ZAR1 is a novel epigenetically inactivated tumour suppressor in lung cancer.
Richter AM; Kiehl S; Köger N; Breuer J; Stiewe T; Dammann RH
Clin Epigenetics; 2017; 9():60. PubMed ID: 28588743
[TBL] [Abstract][Full Text] [Related]
15. TMEM196 acts as a novel functional tumour suppressor inactivated by DNA methylation and is a potential prognostic biomarker in lung cancer.
Liu WB; Han F; Jiang X; Chen HQ; Zhao H; Liu Y; Li YH; Huang C; Cao J; Liu JY
Oncotarget; 2015 Aug; 6(25):21225-39. PubMed ID: 26056045
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of ADAMTS18 by aberrant promoter hypermethylation contribute to lung cancer progression.
Zhang Y; Xu H; Mu J; Guo S; Ye L; Li D; Peng W; He X; Xiang T
J Cell Physiol; 2019 May; 234(5):6965-6975. PubMed ID: 30417422
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
